Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated N'-nitrosonornicotine (deuterated NNN) is a chemically modified form of the tobacco-specific nitrosamine carcinogen N'-nitrosonornicotine (NNN), in which one or more hydrogen atoms are replaced by the stable isotope deuterium. This modification is used primarily for research purposes to study the metabolism and pharmacokinetics of NNN in humans, particularly among users of smokeless tobacco. Deuteration can slow metabolic breakdown due to the kinetic isotope effect, allowing for more precise tracking and quantification in biological samples. The compound itself is not a therapeutic drug but rather a labeled analog used as a probe or tracer in clinical studies investigating carcinogen exposure and metabolism[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterated N'-nitrosonornicotine.